Skip to content
Clinical Trials – home
CroatiaBack to Croatia

Clinical trials in Strmec Samoborski – page 15

259 clinical trials in Strmec Samoborski, Croatia. Every trial is listed in the EU Clinical Trials Register and updated daily.

CroatiaOur site in CroatiaKlinicka-Ispitivanja.hr(opens in a new tab)
Strmec Samoborski at a glance
259
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

259 trials in Strmec Samoborski

Open in trial search

Crohn's disease

Not recruiting

Study of SAR441566 compared to placebo for adults with moderate to severe Crohn's disease

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Balinatunfib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study Comparing Acasunlimab and Pembrolizumab with Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Acasunlimab
  • Sponsor:Genmab A/S

Study Comparing ABP 692 and Ocrelizumab for Patients with Relapsing-Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:Amgen Inc.

Study on Sotagliflozin for Improving Symptoms in Patients with Hypertrophic Cardiomyopathy

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Sotagliflozin
  • Sponsor:Lexicon Pharmaceuticals Inc.

Study on the Long-Term Safety of Obeticholic Acid and Bezafibrate for Patients with Primary Biliary Cholangitis

InvestigationalNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Bezafibrate
  • Sponsor:Intercept Pharmaceuticals Inc.

Urinary tract infection+1

Not recruiting

Study of meropenem-vaborbactam safety and effectiveness in children aged 3 months to 12 years with complicated urinary tract infection or acute pyelonephritis

InvestigationalNo placebo
Countries:CroatiaCroatia
  • Participants:0–17 years
  • Substances:Meropenem
  • Sponsor:Rempex Pharmaceuticals Inc.

Study of Quizartinib with Chemotherapy for Adults with Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Daiichi Sankyo Inc.

Study of Eftilagimod Alfa with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Immutep

Comparison of two doses of cabozantinib (60 mg vs 140 mg) in patients with progressive metastatic medullary thyroid cancer

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Exelixis Inc.

Study Comparing Effects and Safety of CT-P51 and Pembrolizumab with Drug Combination in Patients with Untreated Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Celltrion Inc.

Study Comparing ABP 206 and Nivolumab for Patients with Unresectable or Metastatic Melanoma

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Amgen Inc.

Study on Tolebrutinib for Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years
  • Substances:Tolebrutinib
  • Sponsor:Genzyme Corp.

Other cities in Croatia

The busiest research cities in the country

All 26 cities in Croatia

Clinical research in Strmec Samoborski

What the registry says about research in the country

01 Cardiovascular Research

Clinical trials focusing on hyperlipidaemia management and cardiovascular risk reduction are exploring innovative treatment approaches. The research aims to evaluate the effectiveness of different therapeutic strategies in lowering LDL-C levels for patients with high and very high cardiovascular disease risk.

  • Lipid Management
  • Cardiovascular Risk Reduction
  • Combination Therapy Assessment

These studies examine the comparative efficacy of statin therapy and combination treatments, with a particular focus on achieving specific cholesterol reduction targets in high-risk populations.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.